Pentagon contract could send this $2 AI stock soaring

Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...

Ashley M. Keating net worth and biography

Ashley Keating Biography and Net Worth

Director of Medpace

Ms. Keating is currently the Chief Financial Officer of CincyTech, one of the most active seed-stage investors in the Midwest focused on providing startup capital and guidance to human health and technology companies primarily in Southwest Ohio. From 2005 to April 2016, Ms. Keating worked at PricewaterhouseCoopers (PwC) where she focused on finance, operations, business leadership, and mergers and acquisitions. She began her career in audit services at PwC’s Cincinnati office and later transferred to PwC’s transaction services practice in the New York and London offices. Ms. Keating is a Certified Public Accountant. She received her Bachelor of Business Administration in Accounting and Finance from Ohio University. While at Ohio University Ms. Keating played on the women’s golf team and was named a Division I All-American Scholar.

What is Ashley M. Keating's net worth?: The estimated net worth of Ashley M. Keating is at least $99,390.00 as of March 14th, 2024. Ms. Keating owns 250 shares of Medpace stock worth more than $99,390 as of April 24th. This net worth estimate does not reflect any other investments that Ms. Keating may own. Learn More about Ashley M. Keating's net worth.
How do I contact Ashley M. Keating?: The corporate mailing address for Ms. Keating and other Medpace executives is 5375 MEDPACE WAY, CINCINNATI OH, 45227. Medpace can also be reached via phone at (513) 579-9911 and via email at [email protected]. Learn More on Ashley M. Keating's contact information.
Has Ashley M. Keating been buying or selling shares of Medpace?: Ashley M. Keating has not been actively trading shares of Medpace over the course of the past ninety days. Most recently, Ashley M. Keating sold 250 shares of the business's stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $409.87, for a transaction totalling $102,467.50. Following the completion of the sale, the director now directly owns 250 shares of the company's stock, valued at $102,467.50. Learn More on Ashley M. Keating's trading history.
Who are Medpace's active insiders?: Medpace's insider roster includes Kevin Brady (CFO), Susan Burwig (VP), Stephen Ewald (General Counsel), Jesse Geiger (CFO), Ashley Keating (Director), Tom King (Director), Robert Kraft (Director), and August Troendle (CEO). Learn More on Medpace's active insiders.
Are insiders buying or selling shares of Medpace?: In the last twelve months, insiders at the sold shares 25 times. They sold a total of 841,430 shares worth more than $246,456,813.05. The most recent insider tranaction occured on March, 15th when VP Susan E Burwig sold 102 shares worth more than $41,106.00. Insiders at Medpace own 20.3% of the company. Learn More about insider trades at Medpace.
Information on this page was last updated on 3/15/2024.

Ashley M. Keating Insider Trading History at Medpace

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/14/2024	Sell	250	$409.87	$102,467.50	250
10/26/2021	Sell	2,000	$210.00	$420,000.00
8/4/2021	Sell	1,000	$178.00	$178,000.00

Ashley M. Keating Buying and Selling Activity at Medpace

Medpace Company Overview

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Today's Range

Now: $397.56

$394.00

$421.00

50 Day Range

MA: $397.68

$372.00

$413.31

2 Week Range

Now: $397.56

$189.30

$421.00

Volume

423,395 shs

Average Volume

251,363 shs

Market Capitalization

$12.32 billion

P/E Ratio

40.53

Dividend Yield

N/A

Beta

1.38

Pentagon contract could send this $2 AI stock soaring

From Behind the Markets | Ad

Get all the info here >>>